Dimerix (ASX:DXB), an Australian biopharmaceutical company currently in the clinical-stage, saw its shares reach an impressive 9.7% high at A$0.068, their greatest intraday percentage gain since August 2.

The value of DXB stocks is noted to be at their highest point since September 21.

Dimerix recently received conditional approval by the U.S.

Food and Drug Administration for the commercial brand name Qytovra.

It is worth mentioning that this approval also involves their third phase in clinical trial for a drug candidate to combat focal segmental glomerulosclerosis, a form of kidney disease.

Regardless of recent achievements, the stock was down by 56.3% year-to-date when compared with a 0.43% growth in the benchmark S&P/ASX 200 index as of the last close.

Dimerix is an Australian biopharmaceutical company known for its work in the clinical-stage developing treatments for kidney disease.